Background To recognize risk factors to be a lower life expectancy responder to ranibizumab treatment inside a clinical environment in individuals with neovascular age-related macular degeneration. poorer response towards the intravitreal treatment. solid course=”kwd-title” Lenvatinib Keywords: Ranibizumab, Lucentis, Age-related macular degeneration, Response to treatment Background Ranibizumab is usually a humanised antigen-binding fragment (Fab) that focuses… Continue reading Background To recognize risk factors to be a lower life expectancy